Find Lixivaptan manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 168079-32-1, Vpa-985, Way-vpa-985, Lixar, Vpa 985, N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide
Molecular Formula
C27H21ClFN3O2
Molecular Weight
473.9  g/mol
InChI Key
PPHTXRNHTVLQED-UHFFFAOYSA-N
FDA UNII
8F5X4B082E

Lixivaptan
1 2D Structure

Lixivaptan

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide
2.1.2 InChI
InChI=1S/C27H21ClFN3O2/c1-17-8-9-19(29)13-23(17)26(33)30-20-10-11-22(24(28)14-20)27(34)32-16-21-6-4-12-31(21)15-18-5-2-3-7-25(18)32/h2-14H,15-16H2,1H3,(H,30,33)
2.1.3 InChI Key
PPHTXRNHTVLQED-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=C(C=C(C=C1)F)C(=O)NC2=CC(=C(C=C2)C(=O)N3CC4=CC=CN4CC5=CC=CC=C53)Cl
2.2 Other Identifiers
2.2.1 UNII
8F5X4B082E
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 5-fluoro-2-methyl-n-(4-(5h-pyrrolo(2,1-c)-(1,4)benzodiazepin-10-(11h)-ylcarbonyl)-3-chlorophenyl)benzamide

2. Crtx 080

3. Crtx-080

4. Crtx080

5. N-4-(3-chloro-4-(5h-pyrrolo(2,1-c)(1,4)benzodiazepin-10(11h)-ylcarbonyl)phenyl)-5-fluoro-2-methylbenzamide

6. Vpa 985

7. Vpa-985

8. Way Vpa-985

9. Way-vpa-985

2.3.2 Depositor-Supplied Synonyms

1. 168079-32-1

2. Vpa-985

3. Way-vpa-985

4. Lixar

5. Vpa 985

6. N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c][1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide

7. Crtx-080

8. Vpa985

9. Chembl49429

10. Crtx 080

11. 8f5x4b082e

12. Lixivaptan [usan:inn]

13. 3'-chloro-5-fluoro-4'-(5h-pyrrolo(2,1-c)(1,4)benzodiazepin-10(11h)-ylcarbonyl)-o-toluanilide

14. Benzamide, N-(3-chloro-4-(5h-pyrrolo(2,1-c)(1,4)benzodiazepin-10(11h)-ylcarbonyl)phenyl)-5-fluoro-2-methyl-

15. Benzamide, N-[3-chloro-4-(5h-pyrrolo[2,1-c][1,4]benzodiazepin-10(11h)-ylcarbonyl)phenyl]-5-fluoro-2-methyl-

16. N-(3-chloro-4-(10,11-dihydro-5h-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-carbonyl)phenyl)-5-fluoro-2-methylbenzamide

17. Lixivaptan (usan/inn)

18. Way Vpa-985

19. Way-vpa 985

20. Unii-8f5x4b082e

21. Lixivaptan [usan]

22. Lixivaptan [mi]

23. Lixivaptan [inn]

24. Lixivaptan (vpa-985)

25. Lixivaptan [vandf]

26. Lixivaptan [mart.]

27. Lixivaptan [who-dd]

28. Gtpl2238

29. Schembl1649340

30. Dtxsid00168472

31. Hms3747a19

32. Zinc600399

33. Bcp09167

34. Ex-a1129

35. Vpa-985;way-vpa 985

36. Bdbm50065115

37. Mfcd00937905

38. Akos022181388

39. Cs-7512

40. Db06666

41. Ncgc00485402-01

42. Ac-26832

43. Bs-15602

44. Hy-14185

45. Db-064673

46. Ft-0670828

47. D04752

48. L001508

49. 2-chloro-6,7,8,9-tetrahydrobenzocyclohepten-5-one

50. Q6659958

51. 3-chloro-4-(10,11-dihydro-5h-benzo[e]pyrrolo[1,2-a][1,4]diazepin-10-ylcarbonyl)-1-(5-fluoro-2-methylphenylcarboxamido)benzene

52. 5-fluoro-2-methyl-n-(4-(5h-pyrrolo(2,1-c)-(1,4)benzodiazepin-10-(11h)-ylcarbonyl)-3-chlorophenyl)benzamide

53. Benzamide, N-(3-chloro-4-(5h-pyrrolo(2,1-c)(1,4)benzodiazepin-10(11h)-ylcarbonyl)phenyl)-5-fluoro-2-methyl-;

54. N-[4-(5h,11h-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-carbonyl)-3-chloro-phenyl]-5-fluoro-2-methyl-benzamide

55. N-[4-(5h-pyrrolo[2,1-c][1,4]benzodiazepin-10(11h)-ylcarbony)-3-chlorophenyl]-5-fluoro-2-methylbenzamide

56. N-[4-(5h-pyrrolo[2,1-c][1,4]benzodiazepin-10(11h)-ylcarbonyl)-3-chlorophenyl]-5-fluoro-2-methyl-benzamide

57. N-[4-(5h-pyrrolo[2,1-c][1,4]benzodiazepin-10(11h)-ylcarbonyl)-3-chlorophenyl]-5-fluoro-2-methylbenzamide

58. N-[4-(5h-pyrrolo[2,1-c][1,4]benzodiazepin-10(11h)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2-methylbenzamide

59. N-[4-(5h-pyrrolo[2,1-c][1,4]benzodiazepin10(11h)-ylcarbonyl)-3-chlorophenyl]-5-fluoro-2-methylbenzamide

60. N-4-(3-chloro-4-(5h-pyrrolo(2,1-c)(1,4)benzodiazepin-10(11h)-ylcarbonyl)phenyl)-5-fluoro-2-methylbenzamide

2.4 Create Date
2005-08-09
3 Chemical and Physical Properties
Molecular Weight 473.9 g/mol
Molecular Formula C27H21ClFN3O2
XLogP34.8
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count3
Rotatable Bond Count3
Exact Mass473.1306328 g/mol
Monoisotopic Mass473.1306328 g/mol
Topological Polar Surface Area54.3 Ų
Heavy Atom Count34
Formal Charge0
Complexity753
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Investigated for use/treatment in hyponatremia and congestive heart failure.


Treatment of hyponatraemia


API SUPPLIERS

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty